• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

September 16, 2019
Company Drug/Device Medical Condition Status
Selvita SEL120 acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS) Phase 1b trial initiated enrolling subjects at sites across the U.S.
VBI Vaccines Inc. VBI-1901 in combination with GlaxoSmithKline’s proprietary AS01B adjuvant system recurrent glioblastoma (GBM) Phase 2a trial initiated enrolling 20 subjects with first-recurrent GBM only
Recardio, Inc. dutogliptin in combination with filgrastim post-myocardial infarction Phase 2 trial initiated enrolling 140 subjects at specialized cardiology centers located throughout Europe and the U.S.
Alector, Inc. AL001 frontotemporal dementia (FTD) with specific genetic mutations, including the granulin gene (FTD-GRN) Phase 2 trial initiated enrolling 32 subjects with FTD-GRN and an additional cohort of FTD subjects with a C9orf72 mutation (FTD-C9orf72)
Biohaven Pharma Holding Company Ltd. vazegepant acute treatment of migraine Phase 2/3 trial initiated
Lipidor AB Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01) mild to moderate psoriasis Phase 3 study initiated enrolling 277 subjects at 14 clinics across India
Functional Neuromodulation fornix (DBS-f) mild Alzheimer's Disease Phase 3 study initiated enrolling 210 people 65 years or older with mild Alzheimer's disease at 14 study sites in the U.S., Canada and Germany
EMD Serono evobrutinib relapsing multiple sclerosis (RMS) Two phase 3 studies initiated enrolling 1,900 adult subjects
Nevakar Inc. NVK-002 slow the progression of myopia in children Phase 3 study initiated enrolling 576 child subjects aged 3 to 17 years in Asia, the U.S. and Europe
Netech Delta 3300 arrhythmia 510(k) approval granted by the FDA
Merck KGaA tepotinib metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy Designation granted by the FDA
Horizon Therapeutics plc teprotumumab active thyroid eye disease (TED) Priority Review granted by the FDA
Almirall LLC Aczone 7.5% topical gel acne vulgaris Approval granted by the FDA
Jenkins Eye Care AcrySof IQ PanOptix Trifocal Intraocular Lens (IOL) cataract Approval granted by the FDA
Axonics Modulation Technologies, Inc. implantable rechargeable sacral neuromodulation (“SNM”) device urinary and bowel dysfunction Approval granted by the FDA
Boehringer Ingelheim Pharmaceuticals Ofev (nintedanib) capsules interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD) Approval granted by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing